{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:14:39Z","timestamp":1779387279133,"version":"3.53.1"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma subtype, representing a small fraction of Hodgkin lymphoma or an even smaller fraction of B-cell non-Hodgkin lymphoma, depending on the classification schema used. NLPHL is characterized by rare lymphocyte-predominant (LP) cells interspersed within a complex immunologic architecture. NLPHL immunoarchitecture has led to hypothesis-driven research suggesting the pathogenesis of NLPHL may be driven by aberrant immune responses to commensal microorganisms, including\n                    <jats:italic toggle=\"yes\">Moraxella catarrhalis<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Rothia mucilaginosa<\/jats:italic>\n                    . NLPHL commonly presents in younger adults with asymptomatic lymphadenopathy in early stages. Although late relapses are a well-known feature of this disease, the prognosis is outstanding, nearly mirroring the average life expectancy in Western populations. Management options must carefully weigh the benefits of treatment against the risks of long-term toxicities, including end-organ damage and secondary malignancies. Options utilizing least-toxic approaches include active surveillance, radiation therapy, and combination chemoimmunotherapy for higher-risk presentations. A recent prognostic score, the LP-IPS, derived from large multicenter datasets, may help personalize approaches for patients at higher risk of morbidity\/mortality requiring therapy and identify lower-risk patients for active surveillance or low-toxicity approaches.\n                  <\/jats:p>","DOI":"10.1097\/ppo.0000000000000831","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:28Z","timestamp":1779386428000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8456-0889","authenticated-orcid":false,"given":"Christopher R.","family":"D\u2019Angelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Lunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5]]},"reference":[{"key":"R1-20260521","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1084\/jem.20080809","article-title":"Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis","volume":"205","author":"Brune","year":"2008","journal-title":"J Exp Med"},{"key":"R2-20260521","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0065-230X(02)84009-X","article-title":"Molecular biology of Hodgkin\u2019s lymphoma","volume":"84","author":"K\u00fcppers","year":"2002","journal-title":"Adv Cancer Res"},{"key":"R3-20260521","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"R4-20260521","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"R5-20260521","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.19.00986","article-title":"Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin study group","volume":"38","author":"Eichenauer","year":"2020","journal-title":"J Clin Oncol"},{"key":"R6-20260521","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.23.01655","article-title":"International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma","volume":"42","author":"Binkley","year":"2024","journal-title":"J Clin Oncol"},{"key":"R7-20260521","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/0284186X.2019.1711166","article-title":"Epidemiology of classic and nodular lymphocyte predominant Hodgkin lymphoma in Finland in 1996-2015","volume":"59","author":"Juntikka","year":"2020","journal-title":"Acta Oncol"},{"key":"R8-20260521","doi-asserted-by":"crossref","first-page":"20500","DOI":"10.1038\/s41598-024-69975-3","article-title":"Adult Hodgkin lymphoma incidence trends in the United States from 2000 to 2020","volume":"14","author":"Aslani","year":"2024","journal-title":"Sci Rep"},{"key":"R9-20260521","first-page":"e70269","article-title":"Trends of non-Hodgkin lymphoma incidence among adults in the United States from 2000 to 2020","volume":"8","author":"Aslani","year":"2025","journal-title":"Cancer Rep (Hoboken)"},{"key":"R10-20260521","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.pathol.2025.03.011","article-title":"Increased incidence of Hodgkin lymphoma with decreased association with Epstein-Barr virus in Taiwan: a shift toward Western style","volume":"57","author":"Chang","year":"2025","journal-title":"Pathology"},{"key":"R11-20260521","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clml.2014.01.006","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: biology, diagnosis and treatment","volume":"14","author":"Goel","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R12-20260521","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1002\/cncr.29526","article-title":"Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma","volume":"121","author":"Flowers","year":"2015","journal-title":"Cancer"},{"key":"R13-20260521","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/ajcp\/aqab113","article-title":"Geographic variability of nodular lymphocyte-predominant Hodgkin lymphoma","volume":"157","author":"Xia","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"R14-20260521","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00277-015-2578-6","article-title":"A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma","volume":"95","author":"Strobbe","year":"2016","journal-title":"Ann Hematol"},{"key":"R15-20260521","first-page":"3476","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment","volume":"109","author":"Salvaris","year":"2024","journal-title":"Haematologica"},{"key":"R16-20260521","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood-2016-10-745802","article-title":"T-cell rosettes in nodular lymphocyte\u2013predominant Hodgkin lymphoma","volume":"129","author":"Nguyen","year":"2017","journal-title":"Blood"},{"key":"R17-20260521","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/PAS.0b013e318165b0d6","article-title":"PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Nam-Cha","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R18-20260521","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R19-20260521","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41375-025-02641-3","article-title":"Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","volume":"39","author":"Eichenauer","year":"2025","journal-title":"Leukemia"},{"key":"R20-20260521","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"key":"R21-20260521","first-page":"1889","article-title":"European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes","volume":"96","author":"Anagnostopoulos","year":"2000","journal-title":"Blood"},{"key":"R22-20260521","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.3324\/haematol.2023.282698","article-title":"B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma","volume":"108","author":"Thurner","year":"2023","journal-title":"Haematologica"},{"key":"R23-20260521","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1038\/s41467-020-16375-6","article-title":"Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma","volume":"11","author":"Thurner","year":"2020","journal-title":"Nat Commun"},{"key":"R24-20260521","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1002\/eji.200535594","article-title":"The IgD CH1 region contains the binding site for the human respiratory pathogen Moraxella catarrhalis IgD-binding protein MID","volume":"36","author":"Samuelsson","year":"2006","journal-title":"Eur J Immunol"},{"key":"R25-20260521","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3343\/alm.2013.33.2.145","article-title":"Rothia mucilaginosa pneumonia diagnosed by quantitative cultures and intracellular organisms of bronchoalveolar lavage in a lymphoma patient","volume":"33","author":"Cho","year":"2013","journal-title":"Ann Lab Med"},{"key":"R26-20260521","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ajh.25972","article-title":"Lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma interact with rosetting T cells in an immunological synapse","volume":"95","author":"Bein","year":"2020","journal-title":"Am J Hematol"},{"key":"R27-20260521","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0140-6736(93)91409-F","article-title":"Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori","volume":"342","author":"Wotherspoon","year":"1993","journal-title":"Lancet"},{"key":"R28-20260521","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1200\/JCO.2005.07.083","article-title":"Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy","volume":"23","author":"Ferreri","year":"2005","journal-title":"J Clin Oncol"},{"key":"R29-20260521","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3390\/ijms24032309","article-title":"Defining the Role of the Gut Microbiome in the Pathogenesis and Treatment of Lymphoid Malignancies","volume":"24","author":"Upadhyay Banskota","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R30-20260521","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/PPO.0000000000000047","article-title":"Intestinal microbiome and lymphoma development","volume":"20","author":"Yamamoto","year":"2014","journal-title":"Cancer J"},{"key":"R31-20260521","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin lymphoma, version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 4","key":"R32-20260521","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"key":"R33-20260521","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clml.2013.03.004","article-title":"Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell\/histiocyte-rich large B-cell lymphoma?","volume":"13","author":"Barber","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R34-20260521","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.2019004044","article-title":"How I treat nodular lymphocyte-predominant Hodgkin lymphoma","volume":"136","author":"Eichenauer","year":"2020","journal-title":"Blood"},{"key":"R35-20260521","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.3390\/cancers13123021","article-title":"Pitfalls in the diagnosis of nodular lymphocyte predominant hodgkin lymphoma: variant patterns, borderlines and mimics","volume":"13","author":"Younes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R36-20260521","first-page":"423","article-title":"Progressive transformation of germinal centers in axillary lymph nodes mimicking metastatic lymphadenopathy after breast cancer surgery: a case report","volume":"82","author":"Park","year":"2021","journal-title":"Taehan Yongsang Uihakhoe Chi"},{"key":"R37-20260521","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","article-title":"NCCN guidelines(R) insights: Hodgkin lymphoma, version 2.2022","volume":"20","author":"Hoppe","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R38-20260521","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood-2018-10-877761","article-title":"Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"133","author":"Borchmann","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"R39-20260521","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-142828","article-title":"Outcomes of active surveillance versus initial treatment for nodular lymphocyte predominant Hodgkin Lymphoma: A National Cancer Database (NCDB) Analysis of 2,480 Patients","volume":"136","author":"Cortese","year":"2020","journal-title":"Blood"},{"key":"R40-20260521","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1182\/blood.2019003877","article-title":"Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG","volume":"135","author":"Binkley","year":"2020","journal-title":"Blood"},{"key":"R41-20260521","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"key":"R42-20260521","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J Clin Oncol"},{"key":"R43-20260521","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"key":"R44-20260521","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1097\/HS9.0000000000000837","article-title":"Role of rituximab addition to first-line chemotherapy regimens in nodular lymphocyte-predominant Hodgkin lymphoma: a study by Fondazione Italiana Linfomi","volume":"7","author":"Gotti","year":"2023","journal-title":"Hemasphere"},{"key":"R45-20260521","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.18896","article-title":"R-bendamustine in the treatment of nodular lymphocyte predominant Hodgkin lymphoma-an extended follow-up","volume":"202","author":"Vuolio","year":"2023","journal-title":"Br J Haematol"},{"key":"R46-20260521","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018029140","article-title":"Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"3","author":"Pinnix","year":"2019","journal-title":"Blood Adv"},{"key":"R47-20260521","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/j.ijrobp.2023.06.1697","article-title":"Low dose involved site radiotherapy as single modality treatment for early-stage nodular lymphocyte predominant hodgkin lymphoma","volume":"117","author":"Narula","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R48-20260521","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2021004939","article-title":"Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?","volume":"5","author":"Imber","year":"2021","journal-title":"Blood Adv"},{"issue":"S3","key":"R49-20260521","doi-asserted-by":"crossref","first-page":"e111_70093","DOI":"10.1002\/hon.70093_111","article-title":"111 | BOOM-BOOM radiation prior to lisocabtagene maraleucel is feasible and contributes to high complete response rates for aggressivE B-cell non-Hodgkin lymphoma","volume":"43","author":"D\u2019Angelo","year":"2025","journal-title":"Hematol Oncol"},{"key":"R50-20260521","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ijrobp.2008.09.049","article-title":"Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin\u2019s lymphoma","volume":"74","author":"Haas","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R51-20260521","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin study group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J Clin Oncol"},{"key":"R52-20260521","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"key":"R53-20260521","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41375-019-0609-3","article-title":"Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group","volume":"34","author":"Eichenauer","year":"2020","journal-title":"Leukemia"},{"key":"R54-20260521","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"key":"R55-20260521","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2018-02-836437","article-title":"Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","volume":"132","author":"Eichenauer","year":"2018","journal-title":"Blood"},{"key":"R56-20260521","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.24927","article-title":"High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: a retrospective study by the European society for blood and marrow transplantation-lymphoma working party","volume":"93","author":"Akhtar","year":"2018","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"R57-20260521","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1182\/blood-2025-3620","article-title":"Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: a registry-based study from the EBMT-LWP","volume":"146","author":"Martinez Munoz","year":"2025","journal-title":"Blood"},{"key":"R58-20260521","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hon.2986","article-title":"Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"40","author":"Eichenauer","year":"2022","journal-title":"Hematol Oncol"},{"key":"R59-20260521","doi-asserted-by":"crossref","first-page":"E103","DOI":"10.1002\/ajh.23989","article-title":"Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant hodgkin lymphoma: long-term outcomes from a 30-year experience","volume":"90","author":"Eyre","year":"2015","journal-title":"Am J Hematol"},{"key":"R60-20260521","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2015-08-665505","article-title":"Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution","volume":"127","author":"Kenderian","year":"2016","journal-title":"Blood"},{"issue":"supplement 1","key":"R61-20260521","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood-2024-212106","article-title":"Clinical outcomes of transformed follicular lymphoma with CAR T-cell therapy: a US multicenter real-world analysis","volume":"144","author":"Cortese","year":"2024","journal-title":"Blood"},{"key":"R62-20260521","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1182\/blood.2020009148","article-title":"Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell\/histiocyte-rich large B-cell lymphoma","volume":"137","author":"Trujillo","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"R63-20260521","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2024-211784","article-title":"Clinical features and outcomes of patients with T-cell\/histiocyte-rich large B-cell lymphoma: a single-center analysis","volume":"144","author":"Romancik","year":"2024","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:34Z","timestamp":1779386434000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000831","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-12-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}